Table 5.
AEs during 180-day follow-up
| Characteristic | Omeprazole group (n = 303) | Pantoprazole group (n = 304) | P value |
|---|---|---|---|
| Stent thrombosis [n (%)] | 0 | 0 | — |
| MACEs [n (%)] | 8 (2.6) | 7 (2.3) | 0.80 |
| Cardiac death | 1 (0.3) | 0 | 0.50 |
| Myocardial infarction | 0 | 0 | — |
| Ischemic symptoms driven target vessel revascularization | 3 (1.0) | 1 (0.3) | 0.37 |
| Non-target vessel revascularization | 6 (2.0) | 6 (2.0) | 1.00 |
| Recurrent angina [n (%)] | 30 (9.9) | 24 (7.9) | 0.40 |
| All-cause death [n (%)] | 1 (0.3)a | 1 (0.3)b | 1.00 |
| TIMI bleeding evens [n (%)] | 15 (5.0) | 19 (6.3) | 0.60 |
| Major | 0 | 1 (0.3) | 1.00 |
| Moderate | 0 | 3 (1.0) | 0.25 |
| Minor | 16 (5.3) | 14 (4.6) | 0.71 |
| Stroke [n (%)] | 1 (0.3) | 0 | 0.50 |
| Adverse drug reactions [n (%)] | 17 (5.6) | 19 (6.3) | 0.86 |
| AEs [n (%)] | 50 (16.5) | 44 (14.5) | 0.50 |
aOne patient died due to lung cancer in the omeprazole group
bOne patient died due to acute brainstem hemorrhage in the pantoprazole group